MGNX: MacroGenics, Inc. Stock

by  •  • Comments Off on MGNX: MacroGenics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 85.80
Enterprise Value ($M) -59.77
Book Value ($M) 79.12
Book Value / Share 1.25
Price / Book 1.09
NCAV ($M) 36.64
NCAV / Share 0.58
Price / NCAV 2.34

Profitability (mra)
Return on Invested Capital (ROIC) -0.48
Return on Assets (ROA) -0.22
Return on Equity (ROE) -0.53

Liquidity (mrq)
Quick Ratio 3.11
Current Ratio 3.28

Balance Sheet (mrq) ($M)
Current Assets 182.09
Assets 224.56
Liabilities 145.45
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 149.96
Operating Income -110.58
Net Income -66.97
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -68.37
Cash from Investing 149.30
Cash from Financing 0.96

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
05-15 13G/A Armistice Capital, Llc 9.98 0.32
04-17 13G/A Millennium Management Llc 2.70 -46.28
02-14 13G/A Bb Biotech Ag 15.80 0.00
02-14 13G/A Ra Capital Management, L.p. 0.00 -100.00
02-11 13G Wasatch Advisors Inc 5.60
11-20 13G Frazier Life Sciences Public Fund, L.P. 5.10
11-08 13G/A BlackRock, Inc. 8.60 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT
2025-03-20 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-05 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSU
2024-08-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT T

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-30 227,681 480,040 47.43
2025-05-29 75,100 223,591 33.59
2025-05-28 165,538 407,340 40.64
2025-05-27 83,382 224,732 37.10

(click for more detail)

Similar Companies
LYEL – Lyell Immunopharma, Inc. MCRB – Seres Therapeutics, Inc.
MDGL – Madrigal Pharmaceuticals, Inc. MGTX – MeiraGTx Holdings plc
MIST – Milestone Pharmaceuticals Inc.


Financial data and stock pages provided by
Fintel.io